onr:"swepub:oai:DiVA.org:liu-45524"
Sökning: onr:"swepub:oai:DiVA.org:liu-45524" > Cost-effectiveness ...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
-
- Aspelin, P. (författare)
- Karolinska Institutet
-
- Aubry, P. (författare)
- Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France
-
- Fransson, Sven Göran (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Institutionen för medicin och vård,Kardiologiska kliniken
- visa fler...
- visa färre...
- Karolinska Institutet Department of Cardiology, Ctr Hosp. Universitaire Bichat, Paris, France (creator_code:org_t)
- Elsevier BV, 2005
- 2005
- Engelska.
- Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 149:2, s. 298-303
- Forskningsöversikt (refereegranskat)
Abstract
Ämnesord
Stäng
- Background: Acute renal failure after contrast-induced nephropathy is a clinically important and costly complication after the use of iodine-based contrast media. We investigated the cost and cost-effectiveness of 2 contrast media in patients at high risk of contrast-induced nephropathy. Methods: The analyses were based on a randomized, prospective, multinational clinical study comparing the nephrotoxic effects of an isosmolar nonionic contrast medium, iodixanol, with those of a low-osmolar nonionic contrast medium, iohexol. Resource utilization data were obtained from the study and from a retrospective review of patients' hospital records. Swedish, German, and French unit prices were applied to resources used. Between-group differences in average costs were analyzed using a nonparametric bootstrap method. Results: Resource utilization data for 125 patients were analyzed. Seven contrast media-related serious adverse reactions, of which 6 were acute renal failures, were noted in 6 patients receiving iohexol. Two patients in the iodixanol group had 1 nonserious reaction each. The mean hospitalization cost per patient was €489, €573, and €393 lower after iodixanol than after iohexol using Swedish, German, and French unit prices, respectively. The mean per-patient costs of treating adverse drug reactions were €371, €399, and €445 lower after iodixanol than after iohexol, using the respective unit prices (P = 0.01). Iodixanol was cost-effective compared with iohexol, with both lower costs and better effects related to fewer adverse drug reactions. Conclusions: The isosmolar contrast medium iodixanol appears to be cost-effective when compared with a low-osmolar contrast medium, iohexol, in diabetic patients with renal impairment undergoing angiography. © 2005, Elsevier Inc. All rights reserved.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Aspelin, P.
- Aubry, P.
- Fransson, Sven G ...
- Strasser, R.
- Willenbrock, R.
- Lundkvist, J.
- Artiklar i publikationen
- American Heart J ...
- Av lärosätet
- Linköpings universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
